JP2024505093A5 - - Google Patents

Info

Publication number
JP2024505093A5
JP2024505093A5 JP2023546275A JP2023546275A JP2024505093A5 JP 2024505093 A5 JP2024505093 A5 JP 2024505093A5 JP 2023546275 A JP2023546275 A JP 2023546275A JP 2023546275 A JP2023546275 A JP 2023546275A JP 2024505093 A5 JP2024505093 A5 JP 2024505093A5
Authority
JP
Japan
Prior art keywords
domain
seq
antigen receptor
chimeric antigen
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505093A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014792 external-priority patent/WO2022165440A2/en
Publication of JP2024505093A publication Critical patent/JP2024505093A/ja
Publication of JP2024505093A5 publication Critical patent/JP2024505093A5/ja
Pending legal-status Critical Current

Links

JP2023546275A 2021-02-01 2022-02-01 神経内分泌がんの治療 Pending JP2024505093A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144337P 2021-02-01 2021-02-01
US63/144,337 2021-02-01
PCT/US2022/014792 WO2022165440A2 (en) 2021-02-01 2022-02-01 Treatment of neuroendocrine cancers

Publications (2)

Publication Number Publication Date
JP2024505093A JP2024505093A (ja) 2024-02-02
JP2024505093A5 true JP2024505093A5 (cg-RX-API-DMAC7.html) 2025-02-07

Family

ID=82653957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546275A Pending JP2024505093A (ja) 2021-02-01 2022-02-01 神経内分泌がんの治療

Country Status (7)

Country Link
US (1) US20240415883A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284432A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505093A (cg-RX-API-DMAC7.html)
CN (1) CN116940378A (cg-RX-API-DMAC7.html)
AU (1) AU2022212307A1 (cg-RX-API-DMAC7.html)
CA (1) CA3210515A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022165440A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752684B2 (en) * 2014-07-29 2020-08-25 Cellectis ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
WO2016016343A1 (en) * 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
EP3359689B1 (en) * 2015-10-08 2021-04-14 Decipher Biosciences, Inc. Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancer
TWI841554B (zh) * 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
CA3105816A1 (en) * 2018-07-10 2020-01-16 Precigen, Inc. Ror-1 specific chimeric antigen receptors and uses thereof
EA202192103A1 (ru) * 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
MX2021011494A (es) * 2019-03-26 2021-12-15 Univ California Células t modificadas con el receptor de antígeno quimérico (t car) para el tratamiento de cánceres hematológicos y tumores sólidos.

Similar Documents

Publication Publication Date Title
KR102898514B1 (ko) 다양한 다중 항원의 표적화를 위한 역방향 범용 키메라 항원 수용체 발현 면역 세포, 이의 제조 방법 및 암, 감염증 및 자가면역 장애의 치료를 위한 이의 용도
JP7490915B2 (ja) 抗メソテリンキメラ抗原受容体(car)構築物及びその使用
US12059436B2 (en) BCMA-CAR-T cells
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
Gacerez et al. How chimeric antigen receptor design affects adoptive T cell therapy
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
CN110615843B (zh) 一种包含第三信号受体的嵌合抗原受体及其应用
EP3169703B1 (en) Chimeric antigen receptor and its use
WO2021129559A1 (zh) T细胞受体融合蛋白及其用途
JP2022535429A (ja) 免疫療法のための操作されたナチュラルキラー細胞と操作されたt細胞の組み合わせ
JP2023534808A5 (cg-RX-API-DMAC7.html)
IL279100B1 (en) Diverse antigen binding sites, new platforms and other improvements for cell therapy
JP2021534740A5 (cg-RX-API-DMAC7.html)
AU2017223846A1 (en) Modified cells for immunotherapy
JP2021536265A5 (cg-RX-API-DMAC7.html)
WO2016030414A1 (en) Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP2022527081A5 (cg-RX-API-DMAC7.html)
US20200354451A1 (en) Chimeric antigen receptors comprising a human transferrin epitope sequence
EP3029137B1 (en) Genetic modified pluri- or multipotent stem cells and uses thereof
JP2025081512A5 (cg-RX-API-DMAC7.html)
JP2022513372A5 (cg-RX-API-DMAC7.html)
JP2024536859A5 (cg-RX-API-DMAC7.html)
JP2024504162A5 (cg-RX-API-DMAC7.html)
CN105601752A (zh) 一种多基因重组嵌合抗原受体分子
WO2023044991A1 (zh) 一种特异性靶向肿瘤EpCAM抗原的抗体及应用